Prostate cancer affects a significant number of men in the U.S., with nearly 300,000 new cases diagnosed each year.
Traditional treatment methods, such as androgen deprivation therapy, work by reducing testosterone levels to shrink tumors.
While effective initially, this therapy often leads to unwanted side effects like sexual dysfunction and weight gain.
Over time, it may also lead to castrate-resistant prostate cancer, a more aggressive form of the disease that can develop even under low testosterone levels.
In an effort to improve treatment and reduce these negative outcomes, recent research published in Science Advances offers hopeful news.
Marja Nevalainen, MD, Ph.D., a leading translational medicine physician-scientist, has introduced a new approach aimed at making prostate cancer therapy more patient-friendly and effective.
The cornerstone of Dr. Nevalainen’s research is a novel method of targeting a specific aspect of cell signaling related to cancer growth.
Traditional treatments focus on reducing the activity of the androgen receptor, a protein that plays a crucial role in both the progression of prostate cancer and the body’s use of testosterone.
Over time, however, the androgen receptor can mutate, making standard therapies less effective.
Dr. Nevalainen’s strategy involves the inhibition of Stat5, a protein that increases the levels and activity of the androgen receptor and aids the growth of prostate cancer.
By using a drug that inhibits Stat5, her team was able to significantly reduce androgen receptor levels and slow down tumor growth in cell cultures and human tumor samples tested in vitro and in mice models.
This method of inhibiting Stat5 offers a dual benefit. It not only reduces the growth-promoting actions of the androgen receptor but also minimizes the likelihood of the receptor mutating, thus potentially avoiding the progression to castrate-resistant prostate cancer.
The reduced probability of mutation means that the cancer might be controlled for a longer period with fewer side effects.
The promising results from these initial experiments have paved the way for further testing. A new drug that targets Stat5 is currently undergoing Phase II clinical trials.
This phase of testing will determine the effectiveness and safety of the treatment in humans, which is a critical step before any new therapy can be widely available to patients.
The development of this new approach could significantly change the landscape of prostate cancer treatment, offering a more sustainable and patient-friendly option compared to current therapies.
If successful, this could mean a major advancement in managing a disease that impacts the lives of so many individuals and their families.
If you care about cancer, please read studies that a low-carb diet could increase overall cancer risk, and vitamin D supplements could strongly reduce cancer death.
For more information about health, please see recent studies about how drinking milk affects the risks of heart disease and cancer and results showing higher intake of dairy foods linked to higher prostate cancer risk.
The research finding can be found in Science Advances.
Copyright © 2024 Knowridge Science Report. All rights reserved.
